Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline

Key Takeaways Sanofi beat Q3 earnings and sales estimates, driven by Dupixent and new rare disease therapies.Dupixent sales jumped 26.2% year over year driven by strong demand trends.Vaccine sales declined 7.8% amid lower flu demand, but Sanofi maintained 2025 growth guidance.Sanofi (SNY) reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks Consensus Estimate of $1.60. Earnings of €2.91 per share rose 7% on a reported basis and 13.2% on a constant curren ...